Your browser doesn't support javascript.
loading
Show: 20 | 50 | 100
Results 1 - 7 de 7
Filter
Add more filters










Database
Publication year range
1.
Cureus ; 16(4): e57642, 2024 Apr.
Article in English | MEDLINE | ID: mdl-38707085

ABSTRACT

Background This study aimed to determine if the cerebrospinal fluid (CSF) cell count is useful for predicting the infection severity or prognosis in Japanese adults with community-acquired bacterial meningitis. Methodology This study retrospectively evaluated the prognosis of patients diagnosed with community-acquired bacterial meningitis at our hospital from January 2004 to December 2021 using the modified Rankin scale (mRs) (Showa General Hospital; N = 39). Patients were classified into the following two groups: (i) favorable (mRs: 0-3) and (ii) unfavorable (mRs: 4-6). Eight factors were selected and compared with outcomes, and then two factors were evaluated from those, and a multivariate logistic regression was used to determine the significant variables. Results CSF cell count was observed to be associated with poor prognoses (odds ratio (OR) = 0.86, 95% confidence interval (CI) = 0.99995-0.99999, p = 0.0012). Glasgow coma scale (GCS) score on admission was also observed to be associated with poor prognoses (OR = 0.93, 95% CI = 0.89145-0.97290, p = 0.0029). Conclusions Low CSF cell count and low GCS on admission were observed as risk factors for poor prognoses in patients with bacterial meningitis.

3.
Biol Pharm Bull ; 45(9): 1398-1402, 2022.
Article in English | MEDLINE | ID: mdl-36047211

ABSTRACT

Vancomycin (VCM) is a standard treatment for bacterial meningitis. However, little is known about the transferability of VCM to cerebrospinal fluid (CSF), thus evidence of the transferability of VCM to CSF during bacterial meningitis is needed. In this study, we evaluated the concentration of VCM in the plasma and CSF of postoperative neurosurgical patients with bacterial meningitis and evaluated the factors that affect the transferability of VCM to CSF. The concentrations of VCM in plasma (trough) and CSF were determined in eight patients (four males and four females) with bacterial meningitis who were treated with VCM using HPLC. The ratio of the VCM concentrations in CSF/plasma was also calculated by estimating the blood VCM concentration at the same time as the VCM concentration in CSF was measured. The results showed that the VCM concentration in CSF was 0.9-12.7 µg/mL and the CSF/plasma VCM concentration ratio was 0.02-0.62. We examined the effect of drainage on the transferability of VCM to CSF, which showed that the VCM concentration in CSF and the CSF/plasma VCM concentration ratio were significantly higher in patients not undergoing drainage than in patients who were undergoing drainage. The CSF protein and glucose concentrations, which are diagnostic indicators of meningitis, were positively correlated with the VCM concentration in CSF and the CSF/plasma VCM concentration ratio. Thus, VCM transferability to CSF may be affected by changes in the status of the blood-brain barrier and blood-cerebrospinal fluid barrier due to drainage or meningitis.


Subject(s)
Meningitis, Bacterial , Vancomycin , Anti-Bacterial Agents/therapeutic use , Biological Transport , Chromatography, High Pressure Liquid , Female , Humans , Male , Meningitis, Bacterial/cerebrospinal fluid , Meningitis, Bacterial/drug therapy , Vancomycin/therapeutic use
4.
J Infect Chemother ; 28(8): 1216-1219, 2022 Aug.
Article in English | MEDLINE | ID: mdl-35513971

ABSTRACT

INTRODUCTION: Ceftazidime and ceftriaxone are used to treat various gram-negative pathogens, such as Streptococcus pneumoniae and Pseudomonas aeruginosa, and have shown excellent therapeutic efficacy against bacterial meningitis. However, there is insufficient information on the pharmacokinetic characteristics of their cerebrospinal distribution. Here, we investigated the association of clinical laboratory data in cerebrospinal fluid with ceftazidime and ceftriaxone concentration in the cerebrospinal fluid of patients with inflamed meningitis. METHODS: Cerebrospinal fluid samples were collected from eight adult patients with inflamed meningitis who intravenously received either ceftazidime or ceftriaxone (ceftazidime: a total of 25 samples from three patients, ceftriaxone: a total of 12 samples from five patients). Total cell number, protein concentration, and glucose concentration in the cerebrospinal fluid were retrospectively collected from electronic medical charts. All ceftazidime and ceftriaxone concentrations in the cerebrospinal fluid were determined using high-performance liquid chromatography. RESULTS: Both ceftazidime and ceftriaxone concentrations in cerebrospinal fluid correlated with protein concentration in cerebrospinal fluid; however, no significant correlation was observed in total cell number and glucose concentration in cerebrospinal fluid. CONCLUSIONS: This is the first report on the relationship between the cerebrospinal distribution of these antibiotics and clinical laboratory data in cerebrospinal fluid of adult patients with meningitis.


Subject(s)
Ceftriaxone , Meningitis , Adult , Ceftazidime/therapeutic use , Ceftriaxone/pharmacokinetics , Ceftriaxone/therapeutic use , Cephalosporins/therapeutic use , Glucose/therapeutic use , Humans , Meningitis/drug therapy , Retrospective Studies
5.
Int J Infect Dis ; 110: 382-384, 2021 Sep.
Article in English | MEDLINE | ID: mdl-34363968

ABSTRACT

Linezolid has excellent antibiotic activity against gram-positive organisms and is expected to be an alternative to vancomycin for the treatment of bacterial meningitis. Accumulated evidence has shown the superior pharmacokinetic characteristics of linezolid to vancomycin, such as cerebrospinal fluid penetration. However, in the treatment of meningitis, pharmacokinetic information regarding the intra-cerebrospinal distribution of linezolid and the effects of drainage on the linezolid concentration in the cerebrospinal fluid are unclear. This report describes two patient cases, in which the linezolid concentrations in the cerebrospinal fluid were in the following order: subarachnoid space (cisternal drainage and lumbar puncture) ≥ third ventricle > lateral ventricle. In addition, the linezolid concentration in the cerebrospinal fluid, collected via lumbar puncture, tended to increase after removal of the drainage. This report is novel in presenting two cases of meningitis that showed different intra-cerebrospinal distribution of linezolid in various parts of the central nervous system and an increased linezolid concentration in the cerebrospinal fluid after removal of the drainage.


Subject(s)
Meningitis, Bacterial , Oxazolidinones , Acetamides , Anti-Bacterial Agents/therapeutic use , Cerebrospinal Fluid , Humans , Linezolid , Meningitis, Bacterial/drug therapy
6.
J Infect Chemother ; 24(8): 669-673, 2018 Aug.
Article in English | MEDLINE | ID: mdl-29429850

ABSTRACT

Streptococcus suis, a gram-positive facultative anaerobe commonly found in pigs, is an emerging zoonotic pathogen. Herein, we describe a case of a 45-year-old male Japanese meat wholesaler with S. suis meningitis and pyogenic ventriculitis. S. suis was isolated from his blood and cerebrospinal fluid culture, and sequence type (ST) and serotype were confirmed to be ST1 and serotype 2, respectively, by multilocus sequence typing and the Quellung reaction. Magnetic resonance imaging (MRI) revealed right labyrinthitis and pyogenic ventriculitis. The patient was treated with ceftriaxone and ampicillin for 24 days; the treatment was deemed successful based on negative blood cultures on day 4. However, the patient experienced hearing loss and a vestibular nerve disorder. S. suis is a rare pathogen in Japan but can cause severe infection and sequelae. To the best of our knowledge, this is the first report of a human case of pyogenic ventriculitis caused by S. suis. Our findings suggest that S. suis infection should be considered when hearing impairment is present in a patient with bacterial infection and that MRI can help detect ventriculitis, which can necessitate a prolonged treatment duration.


Subject(s)
Cerebral Ventriculitis/microbiology , Meningitis, Bacterial/microbiology , Streptococcal Infections/microbiology , Streptococcus suis/pathogenicity , Anti-Bacterial Agents/therapeutic use , Brain/diagnostic imaging , Cerebral Ventriculitis/diagnostic imaging , Cerebral Ventriculitis/drug therapy , Glucocorticoids/therapeutic use , Humans , Japan , Magnetic Resonance Imaging , Male , Meningitis, Bacterial/diagnostic imaging , Meningitis, Bacterial/drug therapy , Microbial Sensitivity Tests , Middle Aged , Multilocus Sequence Typing , Serogroup , Streptococcal Infections/diagnostic imaging , Streptococcal Infections/drug therapy , Streptococcus suis/drug effects , Streptococcus suis/genetics , Streptococcus suis/isolation & purification
7.
Rinsho Shinkeigaku ; 56(5): 344-7, 2016 05 31.
Article in Japanese | MEDLINE | ID: mdl-27151225

ABSTRACT

A 64-year-old male came to our hospital emergency department with fever and consciousness disturbance. Culture tests of blood and spinal fluid samples revealed meningococci (Neisseria meningitidis), and we made a diagnosis of meningococcal meningitis. Brain magnetic resonance imaging (MRI) findings revealed ventriculitis. Ceftriaxone was administered for 17 days, however, relapse was noted after that was discontinued, with neutropenia and renal impairment thought to be adverse reactions to the beta-lactam antibiotic. Hence, treatment was switched to oral administration of moxifloxacin for a total of 12 weeks, including in an outpatient setting. After moxifloxacin was discontinued, no side effects or relapse were seen, and treatment was ended. Although antibacterial agents generally show favorable effects for meningococcal meningitis, we consider that sufficient antimicrobial therapy is difficult in cases complicated with ventriculitis.


Subject(s)
Cerebral Ventriculitis/drug therapy , Cerebral Ventriculitis/etiology , Meningitis, Meningococcal/complications , Meningitis, Meningococcal/drug therapy , Administration, Ophthalmic , Anti-Bacterial Agents/administration & dosage , Anti-Bacterial Agents/adverse effects , Ceftriaxone/administration & dosage , Ceftriaxone/adverse effects , Cerebral Ventriculitis/diagnostic imaging , Drug Substitution , Fluoroquinolones/administration & dosage , Humans , Magnetic Resonance Imaging , Male , Meningitis, Meningococcal/diagnosis , Middle Aged , Moxifloxacin , Recurrence , Treatment Outcome
SELECTION OF CITATIONS
SEARCH DETAIL
...